top of page
MigVax is developing an oral COVID-19 sub-unit vaccine.
MigVax, an affiliate of The Migal Galilee Research Institute, is a startup developing Migvax-101, a novel oral subunit COVID-19 vaccine that has demonstrated effectivity in pre-clinical tests as a booster for previously vaccinated persons.
CEPI announces first funding awards to MigVax in quest to develop broadly protective coronavirus vaccines (read more)
bottom of page